Organon and Samsung Bioepis Expand Commercialisation Agreement to Broaden Biosimilar Access in Australia

Shots: Organon & Samsung Bioepis have expanded their development and commercialisation agreement to commercialise a new biosimilar in Australia As per the deal, Organon will receive exclusive commercial rights to the biosimilar in Australia while Samsung Bioepis will be responsible for full development, manufacturing & regulatory responsibilities The amended agreement expands their collaboration to 4 biosimilars in Australia, broadening access to biosimilar medicines across multiple therapeutic areas Ref: Organon  |   Image: Organon & Samsung Bioepis   |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com The post Organon and Samsung Bioepis Expand Commercialisation Agreement to Broaden Biosimilar Access in Australia appeared first on PharmaShots.